SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US OTC > Biotechs >

NeoStem (NBS)

Add NBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator andy e
Search This Board:
Last Post: 3/3/2015 8:20:49 AM - Followers: 104 - Board type: Free - Posts Today: 1

NeoStem, Inc (NBS) 





Company Information:

420 Lexington Avenue
Suite 450

New York, New York 10170

Telephone: 212-584-4180
Fax: 646-514-7787


CIK:  0000320017


NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and comprises a separate therapeutic technology platform in addition to the current three pillars of healthcare: pharmaceuticals, biologics and medical devices. Modern cell-based therapies have progressed from the first recorded human to human blood transfusion 200 years ago through to the advanced cellular therapies of today including bone marrow and organ transplantation, tissue banking and reproductive in vitro fertilization and future therapies being investigated to treat cancer, cardiologic, neurologic, ophthalmic and orthopedic diseases among others. We anticipate that cellular therapies will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization (“CDMO”) providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
Progenitor Cell Therapy, LLC, our wholly owned subsidiary (“PCT”), is a leading CDMO in the cellular therapy industry. Since its inception in 1997, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services.
Our wholly-owned subsidiary, Amorcyte, LLC (“Amorcyte”), which we acquired in October 2011, is developing our own cell therapy, AMR-001, for the treatment of cardiovascular disease. AMR-001 represents our most clinically advanced therapeutic product candidate and enrollment for our Phase 2 PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post Acute Myocardial Infarction (“AMI”) patients commenced in 2012. We expect to complete enrollment for this study in 2013 with the first data readout available six to eight months thereafter. If approved by the U.S. Food and Drug Administration ("FDA") and/or other worldwide regulatory agencies, AMR-001 would address a significant unmet medical need in the treatment of AMI, potentially improving the quality and longevity of life for those afflicted, and position the Company to capture a meaningful share of the worldwide AMI market.
Through our majority-owned subsidiary, Athelos Corporation (“Athelos”), we are collaborating with Becton-Dickinson in early stage clinical development of a therapy utilizing T-cells, collaborating for autoimmune and inflammatory conditions, including but not limited to, graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection. We plan to investigate the clinical feasibility of nTreg-based therapeutics to prevent and/or treat type 1 diabetes, graft vs. host disease, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection and expect to file an Investigational New Drug Application ("IND") with the FDA in 2013 and commence human clinical studies in one of these disease conditions thereafter.
Our pre-clinical assets include our VSEL TM (Very Small Embryonic Like) Technology platform for which we expect to file an IND with the FDA in late 2013 or early 2014 to initiate an National Institutes of Health ("NIH") funded human clinical studies treating periodontitis with VSELs TM . We are also working on a Department of Defense funded study of VSELs TM and mesenchymal stem cells for the treatment of chronic wounds.
NeoStem's origins are in adult stem cell collection and storage and we believe that as new therapeutics are developed utilizing one's own stored cells (autologous), the market penetration rate for the collection and storage business may rise sharply from its current low single digits percentage level allowing our developing a network to scale rapidly if the demand grows.
We believe that NeoStem is ideally positioned to be an integrated leader in the cell therapy industry. We have significant basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States, the support of regulatory and logistical expertise and a talented and experienced clinical team. We believe this expertise will allow us to achieve our mission of becoming the premier cell therapy company.






Feature Stories:



Recent News:






Transfer Agent:

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004




Investor Relations:

Robin L. Smith
Phone: +1 (212) 584-4174










All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.


Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.


Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#1677   NeoStem, Inc. Announces 2014 Year-End Financial Results and andy e 03/03/15 08:20:49 AM
#1676 andy e 02/12/15 09:29:49 AM
#1675   Former mgt of Neostem now is with ticker IPO$ 02/08/15 10:31:19 AM
#1674   Ticker symbol BRTX is using stem cells for IPO$ 02/08/15 10:30:44 AM
#1673   Stem cells and heart muscle restoration in Spain: winesnob 02/01/15 06:55:00 PM
#1672   8K out...... andy e 01/17/15 09:30:53 AM
#1671   VIPER we do read your post. Most of thegringo 01/16/15 08:41:11 AM
#1670   ***All in NBS going too 10 easy money imo Hey Ray 01/14/15 01:35:56 PM
#1669   NeoStem and Invetech Announce Agreement to Develop Closed andy e 01/12/15 10:02:32 AM
#1668   Thank You Viperciara 01/09/15 01:24:48 PM
#1667   Well Viper, I, for one, DO read your kenny33 01/09/15 10:35:47 AM
#1666   YES Oppenheimer Starts coverage on NBS as OUTPERFORM!! Viperciara 01/09/15 08:33:47 AM
#1665   Does anybody read my posts? LOL If so Viperciara 01/09/15 08:17:08 AM
#1664   PCT is continuing work on CAR T-Cells, Adoptive Viperciara 01/09/15 08:15:56 AM
#1663   Add Kidney cancer to the pipeline! Viperciara 01/09/15 08:14:05 AM
#1662   Does anybody realize we have this going on Viperciara 01/09/15 07:28:25 AM
#1661   This is a article about cancer! Do Viperciara 01/09/15 07:22:46 AM
#1660   Did you know KITE before you knew they Viperciara 01/09/15 07:12:17 AM
#1659   This is so much BS Viperciara 01/09/15 07:06:20 AM
#1658   Read this Viperciara 01/08/15 08:13:56 AM
#1657   2015 outlook for Bios, they have a nice Viperciara 01/08/15 07:21:39 AM
#1656   They like new management Viperciara 01/08/15 07:17:08 AM
#1655   Dr. Robin Smith THANK YOU for your contributions Viperciara 01/08/15 07:15:38 AM
#1654 Viperciara 01/08/15 07:12:58 AM
#1653   Neostem to present January 12 2015 Viperciara 01/07/15 05:48:04 AM
#1652   New sec filings dated Jan 05, 2015 Viperciara 01/07/15 05:46:39 AM
#1651 Viperciara 01/07/15 05:45:06 AM
#1650   Here is the Interview with Robin and Larsado Viperciara 12/18/14 06:07:50 AM
#1648   Check this news about Insiders buying subslover 12/03/14 03:31:40 PM
#1647   Maxim Comments On Neostem Following KOLs Presentation http://www.smartera maytepper 12/02/14 11:50:48 AM
#1646   $NBS Group Remains Positive On Neostem After Reviewing maytepper 11/24/14 06:15:00 PM
#1645   Bush put the US behind the rest of KarinCA 11/22/14 03:43:29 PM
#1644 andy e 11/21/14 06:10:35 PM
#1643   NeoStem's NBS10 And Data That Matters To Regulators andy e 11/21/14 06:07:00 PM
#1642   Shheesh. Now we have tax loss selling to oxnous 11/18/14 03:44:00 PM
#1641   Results were actually excellent per etpa 11/18/14 12:31:06 PM
#1640   What a sad short line. I have been H2R 11/18/14 09:11:59 AM
#1639   EPIC FAIL - Another stem cell company fails expediter13 11/18/14 08:51:13 AM
#1638 andyshow 11/17/14 05:36:03 PM
#1637   We, nbs ready to take off $ 17.00 ajnapower 11/17/14 10:30:58 AM
#1636   10Q andy e 10/31/14 07:08:53 AM
#1635 andy e 10/31/14 07:07:52 AM
#1634   I just know what I see watching these expediter13 10/13/14 10:19:00 AM
#1633   I dont own it... expediter13 10/13/14 10:11:54 AM
#1632   2.5 mil short, steady since July brownsfan407 10/09/14 05:57:33 PM
#1631   How much do you think we are worth brownsfan407 10/04/14 01:52:11 PM
#1630   I'm always wary of people who talk like Pyrrhonian 10/03/14 07:29:55 PM
#1629   I am not ! They have been working expediter13 10/03/14 11:37:19 AM
#1628   99% failure?! Thanks for not exaggerating.. Pyrrhonian 10/03/14 10:46:06 AM
#1627   I hope no one fails ! EVER ! expediter13 10/03/14 10:40:11 AM